Equillium (EQ) Expected to Announce Earnings on Wednesday

Equillium (NASDAQ:EQ) will likely be posting its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Equillium to post earnings of ($0.14) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last posted its earnings results on Thursday, August 14th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). On average, analysts expect Equillium to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Equillium Stock Down 13.0%

Equillium stock opened at $1.10 on Monday. Equillium has a 52-week low of $0.27 and a 52-week high of $2.35. The firm’s fifty day moving average is $1.49 and its 200 day moving average is $0.89. The company has a market cap of $65.45 million, a price-to-earnings ratio of -1.96 and a beta of 1.57.

Analysts Set New Price Targets

EQ has been the topic of several recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Equillium in a research report on Wednesday, October 8th. Wall Street Zen raised Equillium to a “sell” rating in a research note on Friday, September 5th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $1.00.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. Vanguard Group Inc. raised its holdings in shares of Equillium, Inc. (NASDAQ:EQ) by 59.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,313,946 shares of the company’s stock after buying an additional 489,855 shares during the period. Vanguard Group Inc. owned about 2.21% of Equillium worth $1,879,000 at the end of the most recent reporting period. 27.05% of the stock is owned by hedge funds and other institutional investors.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.